Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Time to Sell?

Key Points

• SGIOY shares opened sharply lower, falling from a prior close of $9.40 to $8.83 before recovering to about $9.20 on low volume.
• Analyst sentiment remains positive: Jefferies and Goldman Sachs upgraded the ADR to “strong buy,” giving the stock a consensus “Buy” rating.
• Shionogi exceeded quarterly expectations, reporting $0.36 in EPS versus a $0.18 estimate and $1.04 billion in revenue versus a $970.69 million consensus forecast.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $9.40, but opened at $8.83. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.20, with a volume of 497 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 14th. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy".

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The firm has a 50-day simple moving average of $9.07 and a two-hundred day simple moving average of $9.47. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.57 billion, a price-to-earnings ratio of 9.15, a price-to-earnings-growth ratio of 3.37 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. As a group, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi's products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.